来源:药渡撰文:Pharmadeep编辑:活力哈哈核心要点抢先看战略加码:丽珠医药斥资10亿元增持丽珠生物,持股比例提升至66.54%,强化生物药研发主导权。输血研发:资金用于支持抗体药物、重组蛋白疫苗等创新管线,优化亏损企业的资本结构。合规护航:关联交易全程透明,严格遵循港深两地上市规则,关键董事回避表决。图片来源:丽珠医药公告1增资细节:10亿现金输血,持股比例跃升丽珠医药(000513.SZ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.